Medically reviewed by Marla Anderson, MD Key Takeaways IV therapy delivers cancer medicine directly into a vein and often ...

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...

LONDON, Jan 31 (Reuters) - (This Jan 31 story has been refiled to clarify that NMC Health is in administration in the headline and paragraph 1) Collapsed former hospital operator NMC Health this week ...

GLP-1 (glucagon-like peptide-1 receptor agonists) like Ozempic and Wegovy continue to make headlines as more research points to the benefits of taking these medications. Traditionally, patients ...

Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...

You know the drill by now. You're sitting in the purgatory of the service center waiting room. Precisely 63 minutes into your wait, the service adviser walks out with a clipboard and calls your name — ...

The subcutaneous formulation of amivantamab reduces administration time and systemic reactions compared to the intravenous version. PALOMA-3 trial results showed noninferiority in pharmacokinetics and ...

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...

The global EV NMC Battery Market was valued at USD 22.8 Billion in 2024 and is projected to reach USD 70.8 Billion by 2030, growing at a CAGR of 14.8% during the forecast period. The surge is fueled ...

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Patients with ≥1 prior line of therapy were ...